Inmed Pharmaceuticals INC. (INM) — SEC Filings

Overview

Inmed Pharmaceuticals INC. (INM) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 18, 2025: InMed Pharmaceuticals Inc. filed an 8-K on December 18, 2025, reporting on matters submitted to a vote of security holders, Regulation FD disclosures, and financial statements. The filing pertains to events occurring on December 17, 2025, with the company's principal executive offices located in Van

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 1 bullish, 4 bearish, 42 neutral, 3 mixed. The dominant filing sentiment for Inmed Pharmaceuticals INC. is neutral.

Filing Type Overview

Inmed Pharmaceuticals INC. (INM) has filed 33 8-K, 4 10-Q, 3 DEF 14A, 1 10-K/A, 2 10-K, 2 S-1/A, 2 S-1, 1 DEFA14A, 1 SC 13G/A, 1 SC 13G with the SEC between Jun 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (50)

• InMed Pharmaceuticals Files 8-K — 8-K · Dec 18, 2025 Risk: low
  InMed Pharmaceuticals Inc. filed an 8-K on December 18, 2025, reporting on matters submitted to a vote of security holders, Regulation FD disclosures, and finan
• InMed Pharmaceuticals Files 8-K — 8-K · Dec 15, 2025 Risk: low
  InMed Pharmaceuticals Inc. filed an 8-K on December 15, 2025, reporting on events that occurred on December 12, 2025. The filing pertains to 'Other Events' and
• InMed Pharmaceuticals Files 8-K — 8-K · Nov 19, 2025 Risk: low
  InMed Pharmaceuticals Inc. filed an 8-K on November 19, 2025, reporting an event on November 18, 2025. The filing indicates a Regulation FD Disclosure and inclu
• InMed Pharma's Q1 Loss Widens, Revenue Dips Amid Going Concern Doubts — 10-Q · Nov 6, 2025 Risk: high
  InMed Pharmaceuticals Inc. reported a net loss of $1,726,899 for the three months ended September 30, 2025, a slight increase from the $1,677,868 net loss in th
• InMed Seeks Shareholder Nod for Major Equity Issuance, Virtual AGM Set — DEF 14A · Nov 3, 2025 Risk: high
  InMed Pharmaceuticals Inc. (INM) is holding its Annual General and Special Meeting virtually on December 17, 2025, to address several key items, including the e
• InMed Pharma Amends 10-K, Discloses Board & Executive Details — 10-K/A · Oct 24, 2025 Risk: medium
  InMed Pharmaceuticals Inc. filed a 10-K/A Amendment No. 1 on October 24, 2025, to include previously omitted Part III information (Items 10-14) and new certific
• InMed Pharmaceuticals Files 8-K: Officer/Director Changes & Financials — 8-K · Oct 16, 2025 Risk: medium
  InMed Pharmaceuticals Inc. filed an 8-K on October 16, 2025, reporting events as of October 14, 2025. The filing indicates changes related to the departure of d
• InMed Pharmaceuticals Announces Board Changes and Compensation Updates — 8-K · Oct 14, 2025 Risk: medium
  InMed Pharmaceuticals Inc. announced on October 9, 2025, a series of significant corporate actions including the departure of two directors, the election of two
• InMed Pharma Pushes Pipeline Amidst Funding Needs — 10-K · Sep 23, 2025 Risk: high
  InMed Pharmaceuticals Inc. (INM) reported a market value of voting and non-voting common equity held by non-affiliates of $3,316,582 as of December 31, 2024, wi
• InMed Pharmaceuticals Files 8-K — 8-K · Sep 8, 2025 Risk: low
  InMed Pharmaceuticals Inc. filed an 8-K on September 8, 2025, reporting an event on September 5, 2025. The filing is a current report and includes financial sta
• InMed Pharma Amends S-1 for Continuous Offering — S-1/A · Aug 1, 2025 Risk: high
  InMed Pharmaceuticals Inc. filed an S-1/A on August 1, 2025, for a delayed or continuous offering of securities under Rule 415, indicating a potential capital r
• InMed Pharmaceuticals Inc. Files Current Report — 8-K · Jul 28, 2025 Risk: low
  InMed Pharmaceuticals Inc. filed an 8-K on July 28, 2025, reporting a current event. The filing details the company's principal executive offices located at Sui
• InMed Files S-1 for Continuous Offering, Signaling Capital Raise — S-1 · Jul 9, 2025 Risk: high
  InMed Pharmaceuticals Inc. (INM) filed an S-1 registration statement on July 9, 2025, for a delayed or continuous offering of securities under Rule 415. The com
• InMed Pharmaceuticals Files 8-K: Material Agreement & Equity Sales — 8-K · Jun 30, 2025 Risk: medium
  InMed Pharmaceuticals Inc. announced on June 24, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales of
• InMed Pharmaceuticals Files 8-K with Corporate Updates — 8-K · Jun 24, 2025 Risk: low
  InMed Pharmaceuticals Inc. filed an 8-K on June 24, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the com
• InMed Pharmaceuticals Files 8-K with Key Corporate Updates — 8-K · Jun 13, 2025 Risk: medium
  InMed Pharmaceuticals Inc. filed an 8-K on June 13, 2025, reporting on several key events as of June 12, 2025. These include entering into a material definitive
• InMed Pharmaceuticals Files Proxy Materials — DEFA14A · May 29, 2025 Risk: low
  InMed Pharmaceuticals Inc. filed a Definitive Additional Materials (DEFA14A) on May 29, 2025. This filing is related to their proxy statement and indicates no f
• InMed Pharmaceuticals Files Proxy Statement — DEF 14A · May 16, 2025 Risk: medium
  InMed Pharmaceuticals Inc. filed its definitive proxy statement on May 16, 2025, for its annual meeting of shareholders. The filing outlines the proposals to be
• InMed Pharmaceuticals Files 8-K Current Report — 8-K · May 13, 2025 Risk: low
  InMed Pharmaceuticals Inc. filed an 8-K on May 13, 2025, reporting an event on May 12, 2025. The filing indicates it is a current report pursuant to Section 13
• InMed Pharmaceuticals Files Q1 2025 10-Q — 10-Q · May 12, 2025 Risk: low
  InMed Pharmaceuticals Inc. filed its quarterly report for the period ending March 31, 2025. The company, incorporated in British Columbia, Canada, operates in t
• InMed Pharmaceuticals Files 8-K — 8-K · Apr 25, 2025 Risk: low
  InMed Pharmaceuticals Inc. filed an 8-K on April 25, 2025, reporting on other events and financial statements. The filing does not contain specific financial fi
• InMed Pharmaceuticals Files 8-K — 8-K · Apr 8, 2025 Risk: low
  InMed Pharmaceuticals Inc. filed an 8-K on April 8, 2025, reporting an event that occurred on April 4, 2025. The filing indicates 'Other Events' and 'Financial
• InMed Pharmaceuticals Inc. Reports Board and Executive Changes — 8-K · Feb 14, 2025 Risk: medium
  InMed Pharmaceuticals Inc. announced on February 10, 2025, a change in its board of directors and executive compensation arrangements. The filing details the de
• InMed Pharmaceuticals Files 8-K — 8-K · Feb 13, 2025 Risk: low
  InMed Pharmaceuticals Inc. filed an 8-K on February 13, 2025, reporting an event on February 12, 2025. The filing is categorized under Regulation FD Disclosure
• InMed Pharmaceuticals Files Q3 2024 10-Q — 10-Q · Feb 12, 2025 Risk: medium
  InMed Pharmaceuticals Inc. filed its 10-Q for the quarterly period ended December 31, 2024. The company, incorporated in British Columbia, Canada, is involved i
• InMed Pharmaceuticals Files 8-K — 8-K · Feb 3, 2025 Risk: low
  InMed Pharmaceuticals Inc. filed an 8-K on February 3, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not con
• InMed Pharmaceuticals Inc. Files Current Report — 8-K · Jan 22, 2025 Risk: low
  InMed Pharmaceuticals Inc. filed an 8-K on January 22, 2025, reporting a current event. The filing indicates the company's principal executive offices are locat
• InMed Pharmaceuticals Files 8-K — 8-K · Jan 21, 2025 Risk: low
  InMed Pharmaceuticals Inc. filed an 8-K on January 21, 2025, reporting a current event. The filing does not contain specific financial details or significant bu
• InMed Pharmaceuticals Files S-1/A Amendment — S-1/A · Dec 30, 2024 Risk: medium
  InMed Pharmaceuticals Inc. filed an S-1/A amendment on December 30, 2024, for its registration statement. The filing relates to a proposed offering of securitie
• InMed Pharmaceuticals Files S-1 for Potential Offering — S-1 · Dec 23, 2024 Risk: medium
  InMed Pharmaceuticals Inc. filed an S-1 registration statement on December 23, 2024, indicating plans to offer securities. The company, incorporated in British
• Ares Management to Acquire InMed Pharmaceuticals for $100M — 8-K · Dec 19, 2024 Risk: medium
  InMed Pharmaceuticals Inc. announced on December 18, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of Ares Management LLC
• InMed Pharmaceuticals Inc. Files 8-K: Material Agreement & Equity Sales — 8-K · Dec 18, 2024 Risk: medium
  InMed Pharmaceuticals Inc. announced on December 13, 2024, that it entered into a material definitive agreement. The company also disclosed unregistered sales o
• InMed Pharmaceuticals Files 8-K — 8-K · Nov 20, 2024 Risk: low
  InMed Pharmaceuticals Inc. filed an 8-K on November 20, 2024, reporting an event on November 19, 2024. The filing pertains to Regulation FD Disclosure and Finan
• InMed Pharmaceuticals Files 8-K — 8-K · Nov 15, 2024 Risk: low
  InMed Pharmaceuticals Inc. filed an 8-K on November 14, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the
• InMed Pharmaceuticals Files Q3 2024 Report — 10-Q · Nov 14, 2024 Risk: medium
  InMed Pharmaceuticals Inc. filed its quarterly report for the period ending September 30, 2024. The company, based in Vancouver, Canada, is involved in the phar
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• InMed Pharmaceuticals Files 8-K: Rights, Reg FD, and More — 8-K · Nov 12, 2024 Risk: low
  On November 8, 2024, InMed Pharmaceuticals Inc. filed an 8-K report detailing material modifications to the rights of security holders, a Regulation FD disclosu
• SC 13G Filing — SC 13G · Nov 12, 2024
• InMed Pharmaceuticals Faces Delisting Notice — 8-K · Nov 5, 2024 Risk: high
  InMed Pharmaceuticals Inc. filed an 8-K on November 1, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is base
• InMed Pharmaceuticals Files 2024 Proxy Statement — DEF 14A · Oct 28, 2024 Risk: medium
  InMed Pharmaceuticals Inc. filed its definitive proxy statement on October 28, 2024, for its annual meeting on December 18, 2024. The company, headquartered in
• InMed Pharmaceuticals Files 8-K — 8-K · Oct 24, 2024 Risk: low
  InMed Pharmaceuticals Inc. filed an 8-K on October 24, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the
• InMed Pharmaceuticals to be Acquired by Capstone Development — 8-K · Oct 23, 2024 Risk: medium
  InMed Pharmaceuticals Inc. announced on October 22, 2024, that it has entered into a definitive agreement to be acquired by Capstone Development, LLC. The trans
• InMed Pharmaceuticals Inc. Files 2024 Annual Report — 10-K · Sep 30, 2024 Risk: medium
  InMed Pharmaceuticals Inc. filed its annual report for the fiscal year ended June 30, 2024. The company, incorporated in British Columbia, Canada, operates in t
• InMed Pharmaceuticals Files 8-K — 8-K · Sep 26, 2024 Risk: low
  InMed Pharmaceuticals Inc. filed an 8-K on September 26, 2024, to report other events and financial statements. The filing does not contain specific details abo
• InMed Pharmaceuticals Faces Delisting Concerns — 8-K · Sep 20, 2024 Risk: high
  InMed Pharmaceuticals Inc. filed an 8-K on September 20, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The f
• InMed Pharmaceuticals Files 8-K — 8-K · Aug 21, 2024 Risk: low
  InMed Pharmaceuticals Inc. filed an 8-K on August 21, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not cont
• InMed Pharmaceuticals to Acquire BayMedica for $10M — 8-K · Aug 20, 2024 Risk: medium
  InMed Pharmaceuticals Inc. announced on August 20, 2024, that it has entered into a definitive agreement to acquire BayMedica Inc. for an aggregate purchase pri
• InMed Pharmaceuticals Files 8-K — 8-K · Jul 30, 2024 Risk: low
  InMed Pharmaceuticals Inc. filed an 8-K on July 30, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the com
• InMed Pharmaceuticals Inc. Files 8-K for Material Agreement — 8-K · Jun 28, 2024 Risk: medium
  On June 27, 2024, InMed Pharmaceuticals Inc. entered into a material definitive agreement. The company, incorporated in British Columbia with its principal exec
• InMed Pharmaceuticals Acquires BayMedica for $10M — 8-K · Jun 11, 2024 Risk: medium
  InMed Pharmaceuticals Inc. announced on June 10, 2024, that it has entered into a definitive agreement to acquire BayMedica Inc. for approximately $10 million i

Risk Profile

Risk Assessment: Of INM's 48 recent filings, 7 were flagged as high-risk, 19 as medium-risk, and 22 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Inmed Pharmaceuticals INC.'s most recent 10-Q filing (Nov 6, 2025):

• Revenue: $1,120,121
• Net Income: -$1,726,899
• EPS: ($0.44)
• Cash Position: $9,331,077

Key Executives

• Eric A. Adams
• Netta Jagpal
• Michael Woudenberg
• Eric Hsu
• Andrew Hull
• Nicole Lemerond
• Bryan Baldasare
• Scott Saks

Industry Context

InMed Pharmaceuticals operates in the pharmaceutical drug development sector, focusing on small molecule drug candidates for unmet medical needs, and also in the rare cannabinoid manufacturing sector. The pharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. The cannabinoid market is evolving, with increasing interest in therapeutic applications but also facing regulatory uncertainties and competition.

Top Tags

financials (10) · 8-K (8) · regulatory-filing (6) · Biotechnology (5) · sec-filing (5) · pharmaceuticals (5) · disclosure (4) · Pharmaceuticals (4) · material-agreement (4) · corporate-filing (4)

Key Numbers

• SEC File Number: 001-39685 — Identifies the company's filing history with the SEC.
• Central Index Key: 0001728328 — Unique identifier for the company in the SEC EDGAR system.
• Net Loss: $1.7M — Increased from $1.68M in Q1 2025, indicating continued unprofitability.
• Sales: $1.12M — Decreased by 11.4% from $1.26M in Q1 2025, showing revenue decline.
• Cash and Cash Equivalents: $9.33M — Decreased from $11.08M at June 30, 2025, highlighting cash burn.
• Accumulated Deficit: $119M — As of September 30, 2025, demonstrating significant historical losses.
• Common Shares Outstanding: 2,804,186 — As of October 31, 2025, indicating potential for further dilution.
• Net Loss Per Share (Basic and Diluted): ($0.44) — Significantly improved from ($2.71) in Q1 2025, likely due to increased share count.
• Weighted Average Outstanding Common Shares: 3,954,549 — Increased from 620,127 in Q1 2025, indicating substantial share issuance.
• R&D Expense Decrease: 17% — Research and development expenses decreased to $581,612 from $700,145.
• Potential Share Dilution: 20% — Shareholders are asked to approve the issuance of 20% or more of outstanding common shares, which could significantly dilute existing holdings.
• Annual Meeting Date: December 17, 2025 — The virtual meeting where key proposals, including director elections and share issuance, will be voted on.
• Record Date: October 22, 2025 — Shareholders of record on this date are entitled to vote at the Annual Meeting.
• Fiscal Year End: June 30, 2025 — The period for which audited consolidated financial statements will be received at the meeting.
• Aggregate market value of non-affiliate common equity: $3.32M — as of December 31, 2024, indicating a smaller market capitalization

Related Companies

GOVX · MNOV · QBTS · ZYME

Frequently Asked Questions